RxDoctor Payments Data

Nitin Mahajan, MD

Interventional Cardiology · Houston, TXNPI 1467561902

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 72 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$230
  • Abbott$216
  • Pfizer$174
  • Boston Scientific$136
  • Merck$131
  • Johnson & Johnson$106
  • plus $700 from 14 others

What the payments were for

  • Consulting fees$131%
  • Food & beverage$1,66398%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693 in reported general payments places this provider in the 5th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$256,083
Medicare patients
263
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$206,284
XareltoRivaroxaban134$118,771
EntrestoSacubitril/Valsartan78$66,116
BrilintaTicagrelor36$31,010
FarxigaDapagliflozin Propanediol23$26,555
Ranolazine ErRanolazine173$22,349
MultaqDronedarone Hcl14$10,435
Midodrine Hcl28$3,570
Atorvastatin Calcium453$3,352
Nifedipine ErNifedipine104$3,168
ClopidogrelClopidogrel Bisulfate368$2,805
Flecainide Acetate50$2,240
Metoprolol Succinate256$2,117
Bumetanide76$1,855
Dabigatran EtexilateDabigatran Etexilate Mesylate18$1,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$174$206,284261 claims
Johnson & JohnsonXarelto$106$118,771134 claims
NovartisEntresto$106$66,11678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →